Alloy is a biotech company that works to expedite drug discovery and democratize the drug innovation process. Following Alloy’s series C funding round, the company expanded from antibody technology discovery into T-cell receptors, according to the Oct. 3 Alloy news release.
The company plans to use the proceeds from the latest round to fund pre-competitive drug discovery technologies and explore partnerships.
The funding round was led by 8VC and Mubadala Capital, with participation from Thiel Capital, Presight Capital and Founders Fund.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.